Abstract: The present invention is concerned with indolin-2-one and 1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives of general formula I wherein Ar1, A2, R1, R2, R3, X and n are as described herein and pharmaceutically acceptable salts thereof for treatment of central nervous system disorders

Abstract: The present invention relates to compounds of formula I wherein R1? is CH3; R1 is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1? and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, methyl, ethyl, isopropyl, tertbutyl, cyclopropyl, hydroxmethyl, or 2-propyl-2-ol; R3 is Cl, F, CF3, methyl, methoxy, isopropyl, cyano or cyclopropyl; R4 is hydrogen, methyl, F or Cl; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.

Abstract: The invention relates to mimetic peptides of epitope(s) of Apolipoprotein A-I, diagnostic immunoassays comprising such mimetic peptides, as well as methods for diagnosing and methods for preventing and/or treating a cardiovascular disease.

Abstract: The present patent application describes a stirrer comprising a combination of at least one axially-conveying element and at least one radially-conveying element relative to the rotary shaft of the stirrer wherein the largest diameter of the at least one axially-conveying element is equal to or less than the inner diameter di of the radially-conveying element. In one embodiment the stirrer according to the invention is a combination of one anchor stirrer with at least one inclined-blade stirrer. Furthermore the use of the stirrer according to the invention for the culture of cells in a dialysis method is described.

Abstract: A thermal management system for an enclosure containing electrical components includes a thermoelectric cooling unit for controlling temperature inside the enclosure and a controller for the cooling unit, the controller being configured so that it can be installed within and protected by the enclosure, rather than requiring its own separate secure enclosure. The controller can further be installed within a housing of the thermoelectric cooling unit, which housing does not increase the footprint of the cooling unit.

Abstract: An adapter includes a body piece with an open container end side and a dispenser end side opposite to the container end side, and a collar piece arranged around the body piece. The dispenser end side of the body piece has an orifice. The body piece has a longitudinal axis, a cylindrical outer surface, and a cylindrical inner surface with a container thread oriented towards the container end side. The cylindrical outer surface of the body piece is equipped with a cap thread oriented towards the dispenser end side. The cap thread is arranged to interact with an inner thread of the cap for providing a child resistant closure. A collar piece is connected to the body piece that is freely rotatable relative to the body piece around the longitudinal axis of the body piece. The adapter can be used for efficiently and safely connecting a dispenser to container.

Abstract: The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.

Abstract: The invention relates to solid dispersions of poorly water soluble compounds, in particular Compound A as disclosed herein, formed by solvent co-precipitation or spray drying, resulting in improved bioavailability, safety and tolerability of said compounds.

Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R5, A1, A2, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to compounds of formula of formula I wherein R, R1. R2, R2?, R3, R4, R5, L1, L2 and N are as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula I.

Abstract: The present invention relates to a mutant transaminase with increased transaminase activity relative to the wild-type transaminase, a fusion protein comprising the transaminase, a polynucleotide coding for the transaminase, a host cell comprising the polynucleotide, mutant transaminase and/or fusion protein, a method of producing an amine with the mutant transaminase or fusion protein and the use of the mutant transaminase or fusion protein for the production of an amine.

Abstract: The present invention relates to compounds of formula I wherein R1 is hydrogen, F or Cl; L is a bond or lower alkylene; R2 is —(CH2)nO-lower alkyl, lower alkyl substituted by halogen, —(CH2)nC(O)O-lower alkyl, phenyl substituted by lower alkyl or halogen, or is a 5 or 6-membered heteroaryl group, selected from pyridinyl, pyrimidinyl, pyridazinyl, thiazolyl, imidazolyl, pyrazolyl or triazolyl, which are optionally substituted by lower alkyl, halogen, lower alkoxy, ?O, benzyloxy, cycloalkyloxy, hydroxy, cyano, lower alkyl substituted by halogen, or by —(CH2)nO-lower alkyl; n is 1, 2 or 3; R3 is hydrogen, lower alkyl or —(CH2)nO-lower alkyl; R4 is phenyl, pyridinyl or pyrimidinyl, optionally substituted by F; Y is CF or CCl; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomers thereof.

Abstract: The present invention relates to compounds of formula I wherein R1? is CH3 R1 is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1? and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, methyl, ethyl, isopropyl, tert-butyl or cyclopropyl; R3 is Cl, F, CF3, cyano, methyl, methoxy or cyclopropyl; R4 is hydrogen, methyl or F; X is N or CH; Y is N or CH; with the proviso that X and Y are not simultaneously CH; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.

Abstract: A collapsible container is provided with a one-way valve. The valve comprises a cupola shaped slitted membrane forming a closure head to allow dispensing a liquid contained in the container by opening the membrane under liquid pressure. When pressure is reduced the membrane will close and prevent the entrance of air into the container. To avoid a deformation of the membrane in counter dispensing direction a supporting column is arranged within the valve ending in a distance from the lower side of the membrane. This column will prevent an opening of the membrane closure head towards the container storage room when air pressure in direction into the container is too high to be borne by the membrane closure head alone.

Abstract: A apparatus for securing a shield body to one or more enclosures can include a plurality of mounting members configured to retain a plurality of fasteners at any of a plurality of locations along the mounting members. A first set of the mounting members can be secured to a second set of the mounting members, using a first set of the fasteners, at any of a plurality of locations along the mounting members of the first set. One or more enclosures can be secured to the second set of the mounting members, using a second set of the fasteners, at any of a plurality of locations along the mounting members of the second set.

Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6 and R7 are as described herein, compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to compounds TAAR receptor antagonists of formula I wherein X, R, L, Ar and R1 are as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric disorders with compounds of formula I.